Inactivation of Suv39h1 Enhances Anti-Tumor Immune Response by Increasing T Cell Activity and Decreasing T Cell Exhaustion During Anti-PD-1 Treatment
PARIS, July 6, 2022 — Mnemo Therapeutics, a biotechnology company
anti-tumor
PARIS, July 6, 2022 — Mnemo Therapeutics, a biotechnology company